gucag006
Posted - 17 hours ago
$CORT As of 3/15/24, the short interests in CORT remained stubbornly high at 20.2M out of the float of 103M, i.e., 20% of shares were shorted. Consider the tute's ownership stands at 83.5% and insiders another 11.4%. it is obvious that most of the shorts were professional shorties behind sophisticated computers connected by state-of-the-art fiber network. The fact that the SP around mid $20's and PE at 26 shows that the shorties are not in control here, and the credits go to the management of CORT. Not only the shorties failed to control with overwhelming force, the company is self-funding a long list of clinical trials for major diseases. Folks, we will see SP>$60 next year and triple digits SP in 2 to 3 years. When the Relacorilant hit the market early next year, we will start to see the retreat of Shorties in droves.
BullYa
Posted - 1 day ago
$CORT Insider Sells $430,475.00 in Stock
JR603
Posted - 2 days ago
$CORT So what kind of payout should investors hope for from the class action suit? I see $14M is the settlement but I assume the lawyers will get their claws into those $$ before the investors get any bite of the apple that's remaining.
Psalms23
Posted - 3 days ago
@insiderbuyingselling $CORT is trending upward slow and steady. Three key factors: 1. Planned buyback; 2. very low debt and 3. diversified product portfolio. The stock presents low downside risk with high upside potential. Vanguard also stepped in with a new investment position. Short position is approx. 22% which makes no sense and indicates stock manipulation. When this unwinds the stock price will reflect its true value.
BullYa
Posted - 1 week ago
$CORT looking forward 25-26 📈 tmrw
Psalms23
Posted - 1 week ago
$CORT Volume was significant around 11 am. This is a major move upward on a stock with 21% short interest.
UncleStock
Posted - 1 week ago
$CORT $UTHR $EXEL $VRTX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE
BullYa
Posted - 1 week ago
$CORT last call
BullYa
Posted - 1 week ago
$CORT now let's go
BullYa
Posted - 1 week ago
$CORT looks like it's an opportunityto load it up right here for starters
ca_rott1487
Posted - 2 weeks ago
$CORT You can still file for this claim.
BullYa
Posted - 3 weeks ago
$CORT $20 should be the bottom in next few days 📉
insiderbuyingselling
Posted - 3 weeks ago
$CORT new insider selling: 2200 shares. http://insiderbuyingselling.com/?t=CORT
gucag006
Posted - 3 weeks ago
$CORT Near term upsides were capped not by the law suite, but by the revenue potential of Korlym. I think the fair market value with Korlym is about $30. The upward movement of the SP can only come from the commercialization of Relacorilant and other cancer drugs. The timing for the appeal court judgement on the patent case should come after the approval of Relacorilant, which should replace Korlyme for the entire Cushing Syndrome population, while Korlym can only serve less than half of this group due to the undesirable side effects of Korlym. The patent case has much less impact on CORT's SP, but the P3 trial of Relacorilant and its subsequent approval and commercialization are much more important to the uplifting of its SP.
gucag006
Posted - 3 weeks ago
$CORT This was an ancient case settled long time ago, and has absolutely no material consequence on CORT's P&L and balance sheet as well as its current and future operations. Folks, please be aware of this is part of a concerted attempt to bring the SP down by the shorties. So, you're informed.
DailyStocksPicks
Posted - 3 weeks ago
$PRGO might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT, $SUPN, $PCRX, $JAZZ For more details https://youtu.be/VTKGlSe8Cn4
ca_rott1487
Posted - 3 weeks ago
$CORT Settles for $14M with investors to end claims over misinformation. you can file for compensation if you were affected by this, here. CasePage:https://11thestate.com/cases/corcept-securities-settlement
gucag006
Posted - 3 weeks ago
$CORT It's hilarious to watch there two guys battling to put long and short SP on the pre-hour ticker tape. You know this time and age, there is no material consequence of these type of activities, other than wasting their time and lunch money.
https://www.nasdaq.com/market-activity/stocks/cort/pre-market-trades
DailyStocksPicks
Posted - 3 weeks ago
$PRGO Perrigo Company plc's stock might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT $SUPN $PCRX $JAZZ For more details https://youtu.be/5WSzPuYhAF0
gucag006
Posted - 02/29/24
$CORT is a small pharma. If you didn't know the company and I told you the long list of self-funded clinical trial the company is currently running, you probably will think this is BP with MC in the hundred billions. Here is the list: 1) Relacorilant P3 trial Single receptor cortisol blocker, potentially may double or triple its revenue as the currently approved drug Korlym is a multiple receptor cortisol blocker, which cannot be used more than half of the Cushing Syndrome patients due to undesirable side effects. 2) Ovarian cancel P3 trial, 3) ALS (Lou Gehrig's disease) P2 trial, 4) NASH (fatty liver) P1 trial, 5) Breast cancer P2 trial, 6) Prostate cancer P2 trial, 7) Alzheimer’s disease P2 trial, 8) PTSD P2 trial, 9) Major depression P2 trial. The company has only one approve drug in the market with revenue less than $500M in 2023. In a few years, CORT will become a well known BP, or be acquired like one.
Yourmatefromdownunder
Posted - 1 month ago
$CORT Adding some additional shares today, building a nice position. Good long term bet here.
dinoz1001
Posted - 1 month ago
$CORT ready to fill that huge gap
Nosh
Posted - 1 month ago
$CORT Looking ready for a bounce here...may do an entry this week.
gucag006
Posted - 1 month ago
$CORT My fellow longs, when the current round of stock buyback is consummated, the outstanding shares will be reduced to about 91 to 92 million shares. To be calibrated, all large biotechs' share outstanding are in the hundreds of millions to billions. Bottom line: not only SP is cheap, but each share is more valuable than others.
Assuming there is no stock split, we will see triple digit SP soon when Relacorilant and ovarian cancer drugs are introduced to the market, but it will only be the beginning of the story as the company's pipeline is long and deep. It will take more than 5 years to go thru those clinical trials, and I think quadruple digit SP is not out of the question had it not been acquired by that time.
insiderbuyingselling
Posted - 1 month ago
$CORT new insider selling: 1000 shares. http://insiderbuyingselling.com/?t=CORT
gucag006
Posted - 1 month ago
$CORT Sharing a conversation.
insiderbuyingselling
Posted - 1 month ago
$CORT new insider selling: 31828 shares. http://insiderbuyingselling.com/?t=CORT
UncleStock
Posted - 1 month ago
$EGRX $INVA $HRMY $CORT suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN
BioTekk
Posted - 1 month ago
$CORT Forget about the patent case. The real gamechanger will be relacorilant. It will take all of Korlym sales. Expect Phase III in April and NDA filing by the end of Q2. Does not make sense to start generic Korlym with a possible approval of relacorilant by Q1/2025.
Psalms23
Posted - 1 month ago
$CORT Company approved a $200 mil stk buyback or approx. 10% of the outstanding shares. Only 90 mil shares will be outstanding. If the patent Appeal holds up in late Fall, the shorts are going to get squeezed. This is a better setup than the Herbalife scorching with Ackman and Icahn. The downside risk remains low with significant upside potential.